-
2023-503481-23-00
5
2023-03-20
Maintenance treatment in metastatic non-squamous lung cancer
-
2022-502917-27-00
5
2023-03-07
Migraine
-
2023-507233-19-00
10
2023-02-16
Treatment of IgAN
-
2023-509332-26-00
4
2023-02-16
Lupus Nephritis Class III-IV, +/- V
-
2023-505634-94-00
10
2023-02-02
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythe
-
2023-505065-91-00
4
2023-01-30
Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small C
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2023-508389-13-00
5
2022-11-08
Combined endpoint of all-cause mortality, kidney failure, and hospital
-
2024-510656-13-00
5
2022-11-08
Migraine
-
2023-504885-50-00
5
2022-11-07
Treatment of children with chronic kidney disease and proteinuria
-
2023-508425-28-00
4
2022-10-24
Chronic Inflammatory Demyelinating Polyneuropathy
-
2024-514746-36-00
1
2022-10-20
Selected tumor indications that are known to express FAP (Fibroblast a
-
2023-504984-17-00
7
2022-10-05
Module 3: advanced/relapsed HER2-negative breast, ovarian, prostate, o
-
2024-512382-13-00
5
2022-10-04
Migraine (with or without aura)
-
2023-508868-30-00
5
2022-09-26
Treatment of stereotypical prolonged seizure
-
2023-507557-16-00
5
2022-08-31
chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
-
2023-507699-38-00
5
2022-08-30
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2024-510950-29-00
5
2022-07-21
Stereotypical prolonged seizure
-
2023-504660-41-00
4
2022-07-11
Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC
-
2023-505347-38-00
9
2022-06-13
B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma
-
2023-508852-21-00
4
2022-06-10
Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer
-
2024-516331-27-00
3
2022-06-10
Participants with BRAF and/or NRAS mutation positive tumors
-
2023-507029-40-00
5
2022-05-09
Genetic carriers of dilated cardiomyopathy causing variants
-
2023-507119-36-00
5
2022-05-09
Malignant melanoma of the skin in patients with locally advanced and f